Shafran S D, Singer J, Zarowny D P, Deschênes J, Phillips P, Turgeon F, Aoki F Y, Toma E, Miller M, Duperval R, Lemieux C, Schlech W F
Department of Medicine, University of Alberta, Edmonton.
J Infect Dis. 1998 Jan;177(1):252-5. doi: 10.1086/517366.
Uveitis occurred in a substantial proportion of AIDS patients receiving rifabutin, 600 mg daily, together with clarithromycin and ethambutol for treatment of Mycobacterium avium complex bacteremia. A case-control study was undertaken to examine potential risk factors for developing uveitis. Of eight parameters examined, only baseline body weight predicted the development of uveitis by both univariate and multivariate analyses (P = .001). The incidence of uveitis was 14% in patients weighing >65 kg, 45% in patients between 55 and 65 kg, and 64% in patients <55 kg. Concomitant therapy with fluconazole, a drug known to raise serum rifabutin concentrations, was not associated with an increased incidence of uveitis. The risk of uveitis was markedly reduced when rifabutin was given at 300 mg daily in combination with clarithromycin and ethambutol.
在接受每日600毫克利福布汀联合克拉霉素和乙胺丁醇治疗鸟分枝杆菌复合菌血症的艾滋病患者中，葡萄膜炎的发生率相当高。开展了一项病例对照研究，以检查发生葡萄膜炎的潜在风险因素。在所检查的八个参数中，只有基线体重通过单因素和多因素分析均能预测葡萄膜炎的发生（P = 0.001）。体重>65千克的患者葡萄膜炎发生率为14%，体重在55至65千克之间的患者为45%，体重<55千克的患者为64%。与已知可提高血清利福布汀浓度的氟康唑联合治疗与葡萄膜炎发生率增加无关。当利福布汀每日300毫克与克拉霉素和乙胺丁醇联合使用时，葡萄膜炎的风险显著降低。
